New Delhi: Taro Pharmaceutical Industries , a unit of Sun Pharma , is recalling over 17,000 units of an antifungal medication in the US due to manufacturing issues, according to the US Food and Drug Administration ( USFDA ). According to its latest Enforcement Report, the US health regulator stated that Hawthorne-based Sun Pharma/ Taro is recalling 17,664 units of Ciclopirox Shampoo , an antifungal medication that treats seborrheic dermatitis , a condition that causes dry, flaky, and itchy skin.

SEATTLE, WA / ACCESS Newswire / December 26, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that it will conduct a reverse stock split of its outstanding shares of common stock, par value $0.001 per share ("Common Stock"), at a ratio of 1-for-18 (the "Reverse Stock Split"). The Reverse Stock Split is expected to

Vitamin C doesn’t just belong in skincare products—it works even better when you eat it. Scientists discovered that vitamin C from food travels through the bloodstream into every layer of the skin, boosting collagen and skin renewal. People who ate two vitamin C–packed kiwifruit daily showed thicker, healthier skin. The findings suggest glowing skin really does start from within.Scientists at the University of Otago, Faculty of Medicine -- Christchurch Ōtautahi, have identified a direct connecti

REDWOOD CITY, Calif. --(BUSINESS WIRE)--Dec. 26, 2025-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that its board of directors has determined to effect a one-for-16 reverse stock split of Adicet’s common stock, par value $0.0001 per share. The reverse stock split ratio approved by the board of directors is within the previously disclosed range of rat

At NSI 2025, Dr. Mohana Rao Patibandla presented India’s first 51-case series on parafascicular BrainPath surgery for intraventricular brain tumors. Intraventricular tumors demand anatomy-respecting surgery. Parafascicular access prioritizes functional preservation while enabling safe tumor removal, offering early Indian clinical evidence” — Dr. Mohana Rao Patibandla at NSI 2025. GUNTUR, ANDHRA PRADESH, INDIA, December 26, 2025 / EINPresswire.com / -- A landmark academic presentation delivered a

Alfa Cytology combines radiolabelling and radiosynthesis services with biodistribution analysis to support preclinical radiopharmaceutical research. NEW YORK, NY, UNITED STATES, December 25, 2025 / EINPresswire.com / -- As the application of radiodiagnostic and therapeutic drugs in tumor research continues to expand, researchers are placing higher demands on quality control and in vivo behavior assessment of radioactive compounds. In radiopharmaceutical research and development, completing radio

RIYADH, SAUDI ARABIA, December 25, 2025 / EINPresswire.com / -- King Faisal Specialist Hospital and Research Centre (KFSHRC) has successfully implemented a preventive therapy that slows the progression of Type 1 Diabetes in adults and children aged eight years and older who have been diagnosed at stage two of the disease. The therapy was first administered to two eligible patients who met the approved protocol’s criteria, marking a major step toward earlier preventive intervention in a condition

Predictive analytics platform expands beyond commodity markets to tackle leading cause of maternal mortality, targeting Q2 2026 clinical pilot with benchmarks ST.LOUIS , MO, UNITED STATES, December 25, 2025 / EINPresswire.com / -- Percy Intel, the causal artificial intelligence company, today announced a new research initiative applying its proprietary causal intelligence platform to early detection of postpartum hemorrhage (PPH), the leading cause of maternal death worldwide. The initiative rep

The SuperNAT demonstrates 48.6% higher sensitivity than conventional ELISA, with its clinical validation data accepted for poster at ASN Kidney Week 2025. WASHINGTON, DC, UNITED STATES, December 25, 2025 / EINPresswire.com / -- AlloDx , a pioneer in precision renal diagnostics from Shanghai, announced that clinical validation data for its proprietary SuperNAT (Super Nephrin Antibody Trap) technology platform had been accepted for poster presentation at the American Society of Nephrology's Kidney

TABOSUN® (ipilimumab N01 injection) has been approved in combination with TYVYT® (sintilimab injection) for the neoadjuvant treatment of patients with stage IIB-III resectable microsatellite instability-high or mismatch repair deficient (MSI-H/dMMR) colon cancer. The TABOSUN® and TYVYT® combination therapy significantly improved pathological complete response (pCR) rates and enabled most patients to avoid the burden of postoperative adjuvant chemotherapy. This therapy is the first and only dual-